 Paula Riggs
Concepts (281)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Substance-Related Disorders | 38 | 2024 | 1054 | 4.710 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 18 | 2015 | 425 | 1.740 |
Why?
| | Marijuana Smoking | 5 | 2023 | 250 | 1.440 |
Why?
| | Central Nervous System Stimulants | 9 | 2013 | 182 | 1.270 |
Why?
| | Prescription Drug Misuse | 3 | 2019 | 50 | 1.080 |
Why?
| | Cannabis | 4 | 2023 | 509 | 1.070 |
Why?
| | Prescription Drugs | 2 | 2019 | 110 | 0.960 |
Why?
| | Fluoxetine | 3 | 2019 | 54 | 0.950 |
Why?
| | Conduct Disorder | 6 | 2012 | 160 | 0.860 |
Why?
| | Adolescent Behavior | 7 | 2016 | 500 | 0.820 |
Why?
| | Adolescent | 48 | 2024 | 22281 | 0.790 |
Why?
| | Substance Abuse, Intravenous | 2 | 2016 | 127 | 0.790 |
Why?
| | Mental Disorders | 7 | 2025 | 1138 | 0.710 |
Why?
| | Opioid-Related Disorders | 3 | 2019 | 576 | 0.680 |
Why?
| | Problem Behavior | 1 | 2022 | 101 | 0.680 |
Why?
| | Escherichia coli | 10 | 2021 | 852 | 0.670 |
Why?
| | Hallucinogens | 1 | 2023 | 108 | 0.660 |
Why?
| | Methylphenidate | 6 | 2012 | 49 | 0.640 |
Why?
| | Maltose-Binding Proteins | 7 | 2021 | 13 | 0.620 |
Why?
| | Recombinant Fusion Proteins | 9 | 2021 | 674 | 0.620 |
Why?
| | Psychiatry | 1 | 2022 | 186 | 0.610 |
Why?
| | Escherichia coli Proteins | 8 | 2021 | 206 | 0.600 |
Why?
| | School Health Services | 2 | 2016 | 224 | 0.470 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2019 | 297 | 0.460 |
Why?
| | Health Care Reform | 1 | 2016 | 109 | 0.460 |
Why?
| | Acetic Acid | 1 | 2015 | 21 | 0.460 |
Why?
| | Honey | 1 | 2015 | 11 | 0.460 |
Why?
| | Early Medical Intervention | 1 | 2016 | 61 | 0.450 |
Why?
| | Depression | 2 | 2019 | 1533 | 0.430 |
Why?
| | Homeless Youth | 1 | 2013 | 22 | 0.400 |
Why?
| | Academies and Institutes | 1 | 2013 | 60 | 0.400 |
Why?
| | Carrier Proteins | 6 | 2001 | 736 | 0.400 |
Why?
| | Public Health | 2 | 2016 | 564 | 0.390 |
Why?
| | Mental Health | 3 | 2025 | 776 | 0.390 |
Why?
| | Awards and Prizes | 1 | 2013 | 70 | 0.380 |
Why?
| | Humans | 56 | 2025 | 144261 | 0.370 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 729 | 0.370 |
Why?
| | Depressive Disorder | 4 | 2002 | 374 | 0.360 |
Why?
| | Drug Overdose | 1 | 2016 | 367 | 0.350 |
Why?
| | Analgesics, Opioid | 2 | 2019 | 1131 | 0.340 |
Why?
| | Pemoline | 2 | 2004 | 4 | 0.340 |
Why?
| | Periodicals as Topic | 1 | 2013 | 203 | 0.330 |
Why?
| | Empirical Research | 1 | 2010 | 21 | 0.320 |
Why?
| | Research Subjects | 1 | 2010 | 41 | 0.310 |
Why?
| | Mutant Proteins | 1 | 2010 | 106 | 0.310 |
Why?
| | Psychology, Adolescent | 2 | 2007 | 63 | 0.290 |
Why?
| | Mutation, Missense | 1 | 2010 | 340 | 0.280 |
Why?
| | Diagnosis, Dual (Psychiatry) | 6 | 2015 | 39 | 0.280 |
Why?
| | Neurobiology | 1 | 2007 | 14 | 0.270 |
Why?
| | Education, Continuing | 1 | 2008 | 41 | 0.270 |
Why?
| | Comorbidity | 9 | 2016 | 1646 | 0.260 |
Why?
| | Drug Therapy | 1 | 2008 | 80 | 0.260 |
Why?
| | Schizophrenia | 2 | 2025 | 444 | 0.240 |
Why?
| | Family | 5 | 2022 | 679 | 0.230 |
Why?
| | Drug Prescriptions | 1 | 2008 | 280 | 0.230 |
Why?
| | Juvenile Delinquency | 4 | 2004 | 95 | 0.220 |
Why?
| | Personality Disorders | 3 | 2006 | 77 | 0.220 |
Why?
| | Protein Engineering | 2 | 2010 | 122 | 0.220 |
Why?
| | Protein Disulfide-Isomerases | 3 | 2015 | 11 | 0.220 |
Why?
| | Research | 1 | 2007 | 428 | 0.210 |
Why?
| | Linear Models | 2 | 2018 | 850 | 0.210 |
Why?
| | Medical Marijuana | 1 | 2025 | 123 | 0.200 |
Why?
| | Tobacco Use Disorder | 3 | 2011 | 218 | 0.200 |
Why?
| | Male | 31 | 2021 | 72035 | 0.200 |
Why?
| | Combined Modality Therapy | 6 | 2011 | 1264 | 0.190 |
Why?
| | Protein Folding | 3 | 2015 | 279 | 0.190 |
Why?
| | Dronabinol | 1 | 2025 | 247 | 0.180 |
Why?
| | Adolescent Health | 1 | 2022 | 37 | 0.180 |
Why?
| | Oxidoreductases | 2 | 2015 | 96 | 0.180 |
Why?
| | Young Adult | 6 | 2019 | 13990 | 0.170 |
Why?
| | Patient Care Planning | 1 | 2002 | 169 | 0.170 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2021 | 884 | 0.160 |
Why?
| | Mental Health Services | 1 | 2005 | 459 | 0.160 |
Why?
| | Genetic Vectors | 6 | 2001 | 337 | 0.160 |
Why?
| | Child | 7 | 2023 | 22537 | 0.160 |
Why?
| | Prokaryotic Cells | 1 | 2019 | 6 | 0.150 |
Why?
| | Female | 21 | 2017 | 77976 | 0.150 |
Why?
| | Adult | 13 | 2021 | 40262 | 0.150 |
Why?
| | Epitopes | 1 | 2021 | 485 | 0.150 |
Why?
| | Oxidation-Reduction | 3 | 2019 | 1084 | 0.150 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2008 | 1409 | 0.150 |
Why?
| | Prescriptions | 1 | 2019 | 76 | 0.140 |
Why?
| | Sex Factors | 5 | 2017 | 2096 | 0.140 |
Why?
| | Practice Patterns, Physicians' | 1 | 2008 | 1347 | 0.140 |
Why?
| | Bupropion | 1 | 1998 | 46 | 0.140 |
Why?
| | Treatment Outcome | 6 | 2016 | 11643 | 0.140 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 1998 | 58 | 0.140 |
Why?
| | Disulfides | 3 | 2015 | 96 | 0.140 |
Why?
| | Deoxyribonucleases, Type II Site-Specific | 1 | 1997 | 13 | 0.140 |
Why?
| | Longitudinal Studies | 2 | 2023 | 2926 | 0.130 |
Why?
| | Attention Deficit and Disruptive Behavior Disorders | 1 | 1998 | 55 | 0.130 |
Why?
| | Green Fluorescent Proteins | 1 | 2019 | 405 | 0.130 |
Why?
| | Cytoplasm | 2 | 2015 | 269 | 0.130 |
Why?
| | Motivational Interviewing | 1 | 2019 | 116 | 0.130 |
Why?
| | Antisocial Personality Disorder | 1 | 1998 | 121 | 0.130 |
Why?
| | Clonidine | 1 | 1996 | 33 | 0.120 |
Why?
| | Molecular Sequence Data | 6 | 2010 | 2929 | 0.120 |
Why?
| | Genes, Reporter | 1 | 1997 | 275 | 0.120 |
Why?
| | Chromatography, Affinity | 4 | 2001 | 85 | 0.120 |
Why?
| | Solubility | 2 | 2010 | 242 | 0.120 |
Why?
| | Bayes Theorem | 1 | 2018 | 433 | 0.120 |
Why?
| | Organisms, Genetically Modified | 1 | 2015 | 15 | 0.120 |
Why?
| | Sulfenic Acids | 1 | 2015 | 7 | 0.120 |
Why?
| | Statistical Distributions | 1 | 2015 | 8 | 0.110 |
Why?
| | Problem Solving | 2 | 2006 | 155 | 0.110 |
Why?
| | Chromatography, Ion Exchange | 3 | 2001 | 57 | 0.110 |
Why?
| | Social Behavior Disorders | 1 | 1995 | 14 | 0.110 |
Why?
| | Psychotropic Drugs | 1 | 1995 | 74 | 0.110 |
Why?
| | Antidepressive Agents | 1 | 1997 | 242 | 0.110 |
Why?
| | Placebos | 2 | 2011 | 192 | 0.100 |
Why?
| | Behavior, Addictive | 1 | 2015 | 88 | 0.100 |
Why?
| | Antibody Formation | 1 | 2015 | 294 | 0.100 |
Why?
| | Risk | 1 | 2016 | 909 | 0.100 |
Why?
| | Delayed-Action Preparations | 2 | 2011 | 183 | 0.100 |
Why?
| | Cloning, Molecular | 5 | 2000 | 539 | 0.100 |
Why?
| | Risk Factors | 2 | 2023 | 10699 | 0.100 |
Why?
| | Interpersonal Relations | 2 | 2006 | 399 | 0.100 |
Why?
| | Smoking | 3 | 2011 | 1468 | 0.100 |
Why?
| | Models, Molecular | 3 | 2010 | 1618 | 0.090 |
Why?
| | Colorado | 4 | 2017 | 4562 | 0.090 |
Why?
| | Crystallography, X-Ray | 3 | 2021 | 492 | 0.080 |
Why?
| | Immunoglobulin G | 1 | 2015 | 893 | 0.080 |
Why?
| | Protein Structure, Tertiary | 2 | 2010 | 862 | 0.080 |
Why?
| | Models, Statistical | 1 | 2015 | 677 | 0.080 |
Why?
| | Statistics, Nonparametric | 2 | 2004 | 427 | 0.080 |
Why?
| | DNA | 1 | 1997 | 1460 | 0.080 |
Why?
| | Behavior Therapy | 3 | 2015 | 281 | 0.080 |
Why?
| | Propylamines | 1 | 2010 | 11 | 0.080 |
Why?
| | Periplasmic Proteins | 1 | 2009 | 3 | 0.080 |
Why?
| | Bacteroides fragilis | 1 | 2009 | 14 | 0.080 |
Why?
| | Alcoholic Beverages | 1 | 2010 | 31 | 0.080 |
Why?
| | Polysaccharides | 1 | 2010 | 87 | 0.080 |
Why?
| | Psychiatric Status Rating Scales | 4 | 2011 | 537 | 0.080 |
Why?
| | Protein Structure, Secondary | 1 | 2010 | 369 | 0.070 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 304 | 0.070 |
Why?
| | Alcohol-Related Disorders | 2 | 2011 | 118 | 0.070 |
Why?
| | Epidemiologic Studies | 1 | 2008 | 68 | 0.070 |
Why?
| | Base Sequence | 4 | 2000 | 2187 | 0.060 |
Why?
| | Plasmids | 4 | 2015 | 379 | 0.060 |
Why?
| | Amino Acid Sequence | 2 | 2010 | 2154 | 0.060 |
Why?
| | Harm Reduction | 1 | 2007 | 50 | 0.060 |
Why?
| | Education, Medical, Continuing | 1 | 2008 | 131 | 0.060 |
Why?
| | Kinetics | 1 | 2010 | 1627 | 0.060 |
Why?
| | Citalopram | 1 | 2006 | 32 | 0.060 |
Why?
| | Adaptation, Psychological | 1 | 2011 | 706 | 0.060 |
Why?
| | Health Surveys | 1 | 2008 | 510 | 0.060 |
Why?
| | Marijuana Abuse | 2 | 2005 | 211 | 0.060 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 257 | 0.060 |
Why?
| | Managed Care Programs | 1 | 2005 | 136 | 0.050 |
Why?
| | Patient Selection | 1 | 2009 | 719 | 0.050 |
Why?
| | Mutation | 2 | 2015 | 4085 | 0.050 |
Why?
| | Age of Onset | 1 | 2005 | 536 | 0.050 |
Why?
| | Pilot Projects | 2 | 2000 | 1867 | 0.050 |
Why?
| | Alcohol Drinking | 2 | 2015 | 812 | 0.050 |
Why?
| | Motivation | 2 | 2010 | 605 | 0.050 |
Why?
| | Narcotics | 1 | 2003 | 55 | 0.050 |
Why?
| | Research Design | 3 | 2018 | 1129 | 0.050 |
Why?
| | Patient Education as Topic | 1 | 2008 | 777 | 0.050 |
Why?
| | Aged | 2 | 2016 | 25850 | 0.050 |
Why?
| | Child Behavior | 1 | 2004 | 235 | 0.050 |
Why?
| | Recombinant Proteins | 3 | 2012 | 1367 | 0.050 |
Why?
| | Osmosis | 2 | 2012 | 20 | 0.050 |
Why?
| | Severity of Illness Index | 2 | 2012 | 2917 | 0.050 |
Why?
| | Middle Aged | 3 | 2016 | 35762 | 0.040 |
Why?
| | Safety | 1 | 2004 | 355 | 0.040 |
Why?
| | Alkaline Phosphatase | 2 | 2015 | 143 | 0.040 |
Why?
| | Periplasmic Binding Proteins | 1 | 2001 | 13 | 0.040 |
Why?
| | Periplasm | 1 | 2001 | 12 | 0.040 |
Why?
| | Child, Preschool | 1 | 1996 | 11774 | 0.040 |
Why?
| | Narcotic Antagonists | 1 | 2003 | 204 | 0.040 |
Why?
| | Health Promotion | 1 | 2007 | 774 | 0.040 |
Why?
| | Enteropeptidase | 1 | 2000 | 2 | 0.040 |
Why?
| | Amylose | 1 | 2000 | 4 | 0.040 |
Why?
| | Maltose | 1 | 2000 | 8 | 0.040 |
Why?
| | Drug Compounding | 1 | 2021 | 107 | 0.040 |
Why?
| | Factor Xa | 1 | 2000 | 35 | 0.040 |
Why?
| | Protein Denaturation | 1 | 2000 | 75 | 0.040 |
Why?
| | Durapatite | 1 | 2000 | 36 | 0.040 |
Why?
| | Molecular Imaging | 1 | 2019 | 55 | 0.040 |
Why?
| | Administration, Oral | 2 | 2012 | 847 | 0.040 |
Why?
| | Personality Assessment | 2 | 1997 | 79 | 0.040 |
Why?
| | Parent-Child Relations | 3 | 2006 | 270 | 0.040 |
Why?
| | Genetic Engineering | 1 | 2019 | 93 | 0.040 |
Why?
| | Genes, Bacterial | 2 | 1989 | 166 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2021 | 600 | 0.040 |
Why?
| | Monosaccharide Transport Proteins | 2 | 1988 | 56 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2001 | 477 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2000 | 454 | 0.030 |
Why?
| | ATP-Binding Cassette Transporters | 2 | 1988 | 118 | 0.030 |
Why?
| | Referral and Consultation | 2 | 2009 | 847 | 0.030 |
Why?
| | Cohort Studies | 2 | 2005 | 5935 | 0.030 |
Why?
| | Likelihood Functions | 1 | 2018 | 143 | 0.030 |
Why?
| | Hydrogen Peroxide | 1 | 2019 | 336 | 0.030 |
Why?
| | Biosensing Techniques | 1 | 2019 | 139 | 0.030 |
Why?
| | Magnesium | 1 | 1997 | 155 | 0.030 |
Why?
| | DNA, Recombinant | 1 | 1997 | 48 | 0.030 |
Why?
| | Stress, Psychological | 1 | 2005 | 1147 | 0.030 |
Why?
| | Substrate Specificity | 1 | 1997 | 388 | 0.030 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1997 | 381 | 0.030 |
Why?
| | Catalysis | 1 | 1997 | 322 | 0.030 |
Why?
| | Child Behavior Disorders | 1 | 1997 | 118 | 0.030 |
Why?
| | Ribonuclease, Pancreatic | 1 | 2015 | 12 | 0.030 |
Why?
| | Prevalence | 2 | 2017 | 2815 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2008 | 8243 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2003 | 1559 | 0.030 |
Why?
| | Surface Plasmon Resonance | 1 | 2015 | 89 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2015 | 330 | 0.030 |
Why?
| | Glycosylation | 1 | 2015 | 172 | 0.030 |
Why?
| | Personality Inventory | 1 | 1995 | 134 | 0.030 |
Why?
| | Stochastic Processes | 1 | 2015 | 71 | 0.030 |
Why?
| | Psychotherapy | 2 | 2006 | 186 | 0.030 |
Why?
| | Copper | 1 | 2015 | 113 | 0.030 |
Why?
| | Algorithms | 1 | 2002 | 1834 | 0.030 |
Why?
| | Recurrence | 1 | 1998 | 1134 | 0.030 |
Why?
| | Protein Conformation | 1 | 1997 | 946 | 0.030 |
Why?
| | Substance Abuse Treatment Centers | 2 | 2009 | 46 | 0.030 |
Why?
| | Protein Transport | 1 | 2015 | 441 | 0.030 |
Why?
| | Bacteriophages | 1 | 2015 | 111 | 0.030 |
Why?
| | Computer Simulation | 1 | 2018 | 1025 | 0.020 |
Why?
| | Antibodies | 1 | 2015 | 401 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 850 | 0.020 |
Why?
| | Alcoholism | 1 | 2000 | 808 | 0.020 |
Why?
| | Blotting, Western | 1 | 2015 | 1187 | 0.020 |
Why?
| | Mandatory Programs | 1 | 2012 | 16 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2019 | 1339 | 0.020 |
Why?
| | Thioredoxins | 1 | 2012 | 30 | 0.020 |
Why?
| | Bacterial Proteins | 2 | 1989 | 954 | 0.020 |
Why?
| | Genetic Testing | 1 | 2015 | 478 | 0.020 |
Why?
| | Membrane Proteins | 2 | 1989 | 1165 | 0.020 |
Why?
| | Risk-Taking | 1 | 2015 | 323 | 0.020 |
Why?
| | HIV Infections | 1 | 2007 | 3079 | 0.020 |
Why?
| | Patient Care Team | 1 | 1998 | 686 | 0.020 |
Why?
| | Patient Compliance | 1 | 1996 | 585 | 0.020 |
Why?
| | Ethanol | 1 | 1997 | 625 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 1996 | 704 | 0.020 |
Why?
| | Age Factors | 1 | 1999 | 3313 | 0.020 |
Why?
| | Amino Acids | 1 | 2015 | 521 | 0.020 |
Why?
| | Atomoxetine Hydrochloride | 1 | 2010 | 8 | 0.020 |
Why?
| | Adrenergic Uptake Inhibitors | 1 | 2010 | 14 | 0.020 |
Why?
| | Interview, Psychological | 1 | 2010 | 93 | 0.020 |
Why?
| | United States | 1 | 2008 | 15876 | 0.020 |
Why?
| | Genetic Complementation Test | 1 | 2009 | 66 | 0.020 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2010 | 223 | 0.020 |
Why?
| | Checklist | 1 | 2010 | 105 | 0.020 |
Why?
| | Community Mental Health Centers | 1 | 2009 | 13 | 0.020 |
Why?
| | Temperature | 1 | 2012 | 678 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2012 | 379 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 1995 | 1495 | 0.020 |
Why?
| | Gene Deletion | 1 | 2009 | 387 | 0.020 |
Why?
| | Social Work | 1 | 2009 | 85 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2009 | 402 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2010 | 2025 | 0.010 |
Why?
| | Age Distribution | 1 | 2004 | 397 | 0.010 |
Why?
| | Smoking Prevention | 1 | 2004 | 166 | 0.010 |
Why?
| | Sex Distribution | 1 | 2004 | 380 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2009 | 1050 | 0.010 |
Why?
| | Disease Progression | 1 | 2011 | 2840 | 0.010 |
Why?
| | Counseling | 1 | 2006 | 400 | 0.010 |
Why?
| | Ambulatory Care | 1 | 2007 | 597 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2009 | 1705 | 0.010 |
Why?
| | Models, Biological | 1 | 2009 | 1820 | 0.010 |
Why?
| | Sampling Studies | 1 | 1996 | 99 | 0.010 |
Why?
| | Wechsler Scales | 1 | 1996 | 59 | 0.010 |
Why?
| | Intelligence | 1 | 1996 | 112 | 0.010 |
Why?
| | RNA Probes | 1 | 1995 | 12 | 0.010 |
Why?
| | Blotting, Southern | 1 | 1995 | 85 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 1996 | 527 | 0.010 |
Why?
| | Mood Disorders | 1 | 1996 | 139 | 0.010 |
Why?
| | Aggression | 1 | 1996 | 179 | 0.010 |
Why?
| | Genotype | 2 | 1989 | 1833 | 0.010 |
Why?
| | Time Factors | 1 | 2004 | 7155 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1996 | 1304 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2004 | 6021 | 0.010 |
Why?
| | Incidence | 1 | 1997 | 2870 | 0.010 |
Why?
| | Transformation, Bacterial | 1 | 1989 | 9 | 0.000 |
Why?
| | SEC Translocation Channels | 1 | 1989 | 9 | 0.000 |
Why?
| | Restriction Mapping | 1 | 1989 | 80 | 0.000 |
Why?
| | Lac Operon | 1 | 1989 | 44 | 0.000 |
Why?
| | DNA Restriction Enzymes | 1 | 1988 | 53 | 0.000 |
Why?
| | Genes | 1 | 1988 | 226 | 0.000 |
Why?
| | Cross-Sectional Studies | 1 | 1997 | 5813 | 0.000 |
Why?
|
|
Riggs's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|